Evidence map›Paper›PMID 41194665›Full record

ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2025

Valganciclovir for cytomegalovirus viraemia in advanced HIV disease: a phase 2b randomized placebo-controlled trial of valganciclovir for cytomegalovirus viraemia in adults and adolescents with advanced HIV disease.

Jayne Ellis, Laura Joan Nsangi, Mohammed Rassool, Joseph Musaazi, David S Lawrence, Caleb Skipper, David R Boulware, David B Meya, Sean Wasserman, Joseph N Jarvis and 1 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The indirect effects of cytomegalovirus infection-mechanisms and consequences.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jayne EllisDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.ORCID 0000-0002-7009-9144
Laura Joan NsangiInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Mohammed RassoolClinical HIV Research Unit, a division of the Wits Health Consortium, Helen Joseph Hospital, Johannesburg 2193, South Africa.
Joseph MusaaziInfectious Diseases Institute, Makerere University, Kampala, Uganda.
David S LawrenceDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Caleb SkipperDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
David R BoulwareDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
David B MeyaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Sean WassermanInstitute for Infection and Immunity, City St George's University of London, London EC1V 0HB, UK.
Joseph N JarvisDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Tom BoylesClinical HIV Research Unit, a division of the Wits Health Consortium, Helen Joseph Hospital, Johannesburg 2193, South Africa.

Funding

Impact of longitudinal CMV viremia on opportunistic neuroinfections in advanced HIV diseaseK23NS137968 · NINDS · UNIVERSITY OF MINNESOTA · PI Caleb P Skipper · 2024 to 2026
$718k
Medical Research CouncilNIH HHS K23NS137968NINDS NIH HHS K23 NS137968
6 · The paper itself

Abstract

Mortality among adults hospitalized with advanced HIV disease (AHD; CD4 <200 cells μl

Indexed as

Antiviral AgentsCytomegalovirusCytomegalovirus InfectionsHIV InfectionsValganciclovirViremiaAdolescentAdultClinical Trials, Phase II as TopicDouble-Blind MethodHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicSouth AfricaAntiviral AgentsValganciclovirCMV viraemiacytomegalovirusHIVRCTvalganciclovir

Identifiers

PMID41194665
PMCPMC12590176

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.